[go: up one dir, main page]

MX2020005500A - Derivados novedosos de piperidinilo como inhibidores de la proteasa 7 ubiquitina especifica. - Google Patents

Derivados novedosos de piperidinilo como inhibidores de la proteasa 7 ubiquitina especifica.

Info

Publication number
MX2020005500A
MX2020005500A MX2020005500A MX2020005500A MX2020005500A MX 2020005500 A MX2020005500 A MX 2020005500A MX 2020005500 A MX2020005500 A MX 2020005500A MX 2020005500 A MX2020005500 A MX 2020005500A MX 2020005500 A MX2020005500 A MX 2020005500A
Authority
MX
Mexico
Prior art keywords
sub
inhibitors
specific protease
ubiquitin specific
piperidinyl derivatives
Prior art date
Application number
MX2020005500A
Other languages
English (en)
Inventor
Olivier Geneste
Attila Vasas
András Kotschy
James Brooke Murray
Maïa Chanrion
Csaba Wéber
Balázs Molnár
Árpád Kiss
Alba Macias
Elodie Lewkowicz
Lisa Ivanschitz
Ágnes Strofek
Vilibald Kun
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2020005500A publication Critical patent/MX2020005500A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de la fórmula (I): en donde R1, R2, R3, B, W, Z, m y n son como se definen en la descripción. Los compuestos de la presente invención tienen propiedades pro-apoptóticas y antiproliferativas lo que hace posible utilizarlos en patologías que implican un defecto en la apoptosis, tales como por ejemplo, en el tratamiento de cáncer y de enfermedades inmunes y auto-inmunes.
MX2020005500A 2017-11-29 2018-11-28 Derivados novedosos de piperidinilo como inhibidores de la proteasa 7 ubiquitina especifica. MX2020005500A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1761338 2017-11-29
PCT/EP2018/082766 WO2019105963A1 (en) 2017-11-29 2018-11-28 New piperidinyl derivatives as inhibitors of ubiquitin specific protease 7

Publications (1)

Publication Number Publication Date
MX2020005500A true MX2020005500A (es) 2020-08-31

Family

ID=62091951

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005500A MX2020005500A (es) 2017-11-29 2018-11-28 Derivados novedosos de piperidinilo como inhibidores de la proteasa 7 ubiquitina especifica.

Country Status (17)

Country Link
US (1) US11332472B2 (es)
EP (1) EP3717482A1 (es)
JP (1) JP2021504388A (es)
KR (1) KR20200094176A (es)
CN (1) CN111542524A (es)
AR (1) AR113846A1 (es)
AU (1) AU2018377976A1 (es)
BR (1) BR112020010547A2 (es)
CA (1) CA3083320C (es)
EA (1) EA202091260A1 (es)
IL (1) IL274737A (es)
MA (1) MA51202A (es)
MX (1) MX2020005500A (es)
RU (1) RU2020120043A (es)
SG (1) SG11202004631RA (es)
TW (1) TW201925202A (es)
WO (1) WO2019105963A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118108744A (zh) * 2020-01-08 2024-05-31 四川科伦博泰生物医药股份有限公司 异噻唑并嘧啶酮类化合物，包含其的药物组合物及其用途
CN113087718B (zh) * 2020-01-09 2024-02-09 四川科伦博泰生物医药股份有限公司 噻吩并嘧啶酮类化合物及其医药应用
GB202001980D0 (en) * 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
CN112047933B (zh) * 2020-10-15 2022-06-14 郑州大学 喹唑啉酮类usp7抑制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41291A (fr) * 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
AR103297A1 (es) * 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
FR3052452B1 (fr) * 2016-06-10 2018-06-22 Les Laboratoires Servier Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
WO2019105963A1 (en) 2019-06-06
BR112020010547A2 (pt) 2020-10-27
KR20200094176A (ko) 2020-08-06
EP3717482A1 (en) 2020-10-07
MA51202A (fr) 2020-10-07
TW201925202A (zh) 2019-07-01
AR113846A1 (es) 2020-06-17
JP2021504388A (ja) 2021-02-15
RU2020120043A (ru) 2021-12-29
US20200407363A1 (en) 2020-12-31
US11332472B2 (en) 2022-05-17
CN111542524A (zh) 2020-08-14
IL274737A (en) 2020-07-30
CA3083320C (en) 2022-08-16
AU2018377976A1 (en) 2020-06-04
EA202091260A1 (ru) 2020-09-07
SG11202004631RA (en) 2020-06-29
CA3083320A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
ZA202401324B (en) Tyrosine kinase inhibitors
PH12021500014A1 (en) Fused ring compounds
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
CR20200362A (es) CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395)
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
EA201691134A1 (ru) Новые ингибиторы глутаминазы
MA41291A (fr) Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MX2022006768A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
TN2018000119A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
WO2016004807A3 (en) Purine inhibitors of human phosphatidylinositol 3-kinase delta
WO2015123449A3 (en) Compositions and methods of using microrna inhibitors
PH12021551280A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2020005500A (es) Derivados novedosos de piperidinilo como inhibidores de la proteasa 7 ubiquitina especifica.
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
MY188420A (en) Crystalline forms of (s)-afoxolaner
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX2020012065A (es) Compuestos de ciclopentano.
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations